Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Cell Cycle

Volumn 14, Issue 4, 2015, Pages 648-655

  Canfield, Kaleigh ^a   Li, Jiaqi ^a   Wilkins, Owen M ^a   Morrison, Meghan M ^e   Ung, Matthew ^a   Wells, Wendy ^a,b   Williams, Charlotte R ^a   Liby, Karen T ^a,b   Vullhorst, Detlef ^c   Buonanno, Andres ^c   Hu, Huizhong ^d   Schiff, Rachel ^d   Cook, Rebecca S ^e   Kurokawa, Manabu ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; HER2; HER3; HER4; Herceptin

Indexed keywords

AFATINIB; CANERTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERATINIB; PROTEIN KINASE B; SMALL INTERFERING RNA; TRASTUZUMAB; VARLITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, MOUSE; ERBB4 PROTEIN, MOUSE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTS ASSAY; NONHUMAN; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

MOUSE MAMMARY TUMOR VIRUS; MUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; MICE; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-4; TRASTUZUMAB;

EID: 84923613538     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.994966     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137; PMID:11252954; http://dx.doi.org/10.1038/ 35052073
2. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanismbased cancer therapeutics. Cancer Cell 2014; 25:282-303; PMID:24651011; http://dx.doi.org/ 10.1016/j.ccr.2014.02.025
3. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100:8933-8938; PMID:12853564; http://dx.doi.org/10.1073/pnas.1537685100
4. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA 2009; 106:21608-21613; PMID:20007378; http://dx. doi.org/10.1073/pnas.0912101106
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182; PMID:3798106; http://dx.doi.org/10.1126/ science.3798106
6. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26:1066-1072; PMID:18212337; http://dx.doi.org/10.1200/ JCO.2007.13.9949
7. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2C cohort in EGF103009, a phase II study. Lancet Oncol 2009; 10:581-588; PMID:19394894; http://dx.doi.org/10.1016/S1470-2045(09)70087-7
8. Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 2014; 111:1888-98; PMID:25025958; http://dx.doi. org/10.1038/bjc.2014.388
9. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine 2011; 17:461-469; PMID:21399647; http://dx.doi.org/10.1038/ nm.2309
10. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011; 108:5021-5026; PMID:21385943; http://dx.doi. org/10.1073/pnas.1016140108
11. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA 2013; 110:14372-14377; PMID:23940356; http://dx.doi.org/10.1073/pnas. 1303204110
12. Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2C breast cancer models. Breast Cancer Res 2013; 15:R85; PMID:24044505; http://dx.doi.org/10.1186/ bcr3480
13. Kurokawa M, Kim J, Geradts J, Matsuura K, Liu L, Ran X, Xia W, Ribar TJ, Henao R, Dewhirst MW, et al. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal 2013; 6:ra32; PMID:23652204; http://dx.doi.org/10.1126/scisignal.2003741
14. Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M, Muller W, Kent Lloyd KC, Stern DF. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 2006; 25:5664-5672; PMID:16652155; http://dx.doi. org/10.1038/sj.onc.1209574
15. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41:1127-1132; PMID:19718025; http:// dx.doi.org/10.1038/ng.438
16. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodri-guez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med 2013; 5:1019-1034; PMID:23681745; http://dx.doi.org/ 10.1002/emmm.201202343
17. Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009; 8:18-22; PMID:19106609; http://dx.doi. org/10.4161/cc.8.1.7324
18. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94; PMID:12467226
19. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 2007; 67:1228-1238; PMID:17283159; http://dx.doi.org/ 10.1158/0008-5472.CAN-06-3493
20. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/ neu. Cancer Res 2007; 67:6825-6843; PMID:17638894; http://dx.doi.org/10.1158/0008-5472.CAN-07-0765
21. Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun 2011; 407:219-224; PMID:21377448; http://dx.doi.org/10.1016/j. bbrc.2011.03.002
22. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-440; PMID:19411071; http://dx.doi.org/ 10.1016/j.ccr.2009.03.020
23. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 2014; 20:3507-3520; PMID:24879796; http://dx. doi.org/10.1158/1078-0432.CCR-13-2769
24. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924-11932; PMID:18089823; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1885
25. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1046-1051; PMID: 22037378; http://dx.doi.org/10.1038/nbt.1990
26. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1998; 54:105-115; PMID:2898299; http://dx.doi. org/10.1016/0092-8674(88)90184-5
27. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008; 7:1251-1257; PMID:18483313; http://dx.doi.org/10.1158/1535-7163.MCT-08-0023
28. To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res 2014; 7:698-707; PMID:24817481; http://dx.doi.org/ 10.1158/1940-6207.CAPR-14-0047
29. Ni CY, Murphy MP, Golde TE, Carpenter G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294:2179-2181; PMID:11679632; http://dx.doi.org/ 10.1126/science.1065412
30. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Can Ther 2012; 11:1978-1987; PMID:22761403; http://dx.doi.org/ 10.1158/1535-7163.MCT-11-0730
31. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 2013; 4:1592-1605; PMID:24009064
32. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. b1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13:R84; PMID:21884573; http://dx.doi. org/10.1186/bcr2936
33. Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. Journal of Mammary Gland Biology and Neoplasia 2008; 13:235-246; PMID:18437540; http://dx.doi.org/10.1007/s10911-008-9080-x
34. Portier BP, Minca EC, Wang Z, Lanigan C, Gruver AM, Downs-Kelly E, Budd GT, Tubbs RR. HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma. Oncotarget 2013; 10:1662-72; PMID:24091566
35. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 2010; 29:5193-203; PMID:20581867; http://dx.doi.org/10.1038/onc.2010.257